OpenLB
Open Library of Bioscience
Advanced Search
Antioxidants & redox signaling
06 20, 2019;30 (18): 2110-2153.

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Carlo Gabriele Tocchetti, Christian Cadeddu, Daniela Di Lisi, Saveria Femminò, Rosalinda Madonna, Donato Mele, Ines Monte, Giuseppina Novo, Claudia Penna, Alessia Pepe, Paolo Spallarossa, Gilda Varricchi, Concetta Zito, Pasquale Pagliaro, Giuseppe Mercuro
Author Information
  1. Carlo Gabriele Tocchetti: 1 Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  2. Christian Cadeddu: 2 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  3. Daniela Di Lisi: 3 Biomedical Department of Internal Medicine, University of Palermo, Palermo, Italy.
  4. Saveria Femminò: 4 Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  5. Rosalinda Madonna: 5 Center of Aging Sciences and Translational Medicine - CESI-MeT, "G. d'Annunzio" University, Chieti, Italy.
  6. Donato Mele: 7 Cardiology Unit, Emergency Department, University Hospital of Ferrara, Ferrara, Italy.
  7. Ines Monte: 8 Department of General Surgery and Medical-Surgery Specialities, University of Catania, Catania, Italy.
  8. Giuseppina Novo: 3 Biomedical Department of Internal Medicine, University of Palermo, Palermo, Italy.
  9. Claudia Penna: 4 Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  10. Alessia Pepe: 9 U.O.C. Magnetic Resonance Imaging, Fondazione Toscana G. Monasterio C.N.R., Pisa, Italy.
  11. Paolo Spallarossa: 10 Clinic of Cardiovascular Diseases, IRCCS San Martino IST, Genova, Italy.
  12. Gilda Varricchi: 1 Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  13. Concetta Zito: 12 Division of Cardiology, Clinical and Experimental Department of Medicine and Pharmacology, Policlinico "G. Martino" University of Messina, Messina, Italy.
  14. Pasquale Pagliaro: 4 Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  15. Giuseppe Mercuro: 2 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
PMID: 28398124 DOI: 10.1089/ars.2016.6930

Abstract

Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. CTX can occur within a few days or many years after treatment. Type I CTX is associated with irreversible cardiac cell injury, and it is typically caused by anthracyclines and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and more targeted drugs, and it is associated with reversible myocardial dysfunction. Therefore, patients undergoing anti-cancer treatments should be closely monitored, and patients at risk of CTX should be identified before beginning treatment to reduce CTX-related morbidity. Genetic profiling of clinical risk factors and an integrated approach using molecular, imaging, and clinical data may allow the recognition of patients who are at a high risk of developing chemotherapy-related CTX, and it may suggest methodologies to limit damage in a wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer treatments is a very active field of research. Further investigations will be necessary to uncover the hallmarks of cancer from a redox perspective and to develop more efficacious antineoplastic therapies that also spare the cardiovascular system.

Keywords

ErbB2 inhibitors cancer immunotherapy chemotherapy oxidative/nitrosative stress tyrosine kinase inhibitors vascular endothelial growth factor

References

  1. Circulation. 1999 Jul 27;100(4):407-12 [PMID: 10421602]
  2. Cancer Prev Control. 1999 Apr;3(2):145-59 [PMID: 10474762]
  3. Life Sci. 1999;65(12):1265-74 [PMID: 10503942]
  4. Circulation. 1999 Nov 16;100(20):2100-7 [PMID: 10562267]
  5. Eur J Nucl Med. 2000 Jun;27(6):686-93 [PMID: 10901455]
  6. Circulation. 2000 Oct 24;102(17):2105-10 [PMID: 11044428]
  7. Science. 2001 Jan 12;291(5502):319-22 [PMID: 11209085]
  8. N Engl J Med. 2001 Mar 15;344(11):783-92 [PMID: 11248153]
  9. Br J Pharmacol. 2001 Apr;132(7):1365-73 [PMID: 11264228]
  10. Scanning. 2001 Jan-Feb;23(1):1-8 [PMID: 11272331]
  11. N Engl J Med. 2001 Sep 27;345(13):995-6 [PMID: 11575295]
  12. Clin Sci (Lond). 2001 Dec;101(6):601-7 [PMID: 11724646]
  13. J Appl Toxicol. 2001 Nov-Dec;21(6):469-73 [PMID: 11746193]
  14. J Clin Oncol. 2002 Mar 1;20(5):1215-21 [PMID: 11870163]
  15. Nat Med. 2002 May;8(5):459-65 [PMID: 11984589]
  16. Ann Oncol. 2002 Mar;13(3):484-5 [PMID: 11996484]
  17. Ann Oncol. 2002 Apr;13(4):503-12 [PMID: 12056699]
  18. Circulation. 2002 Jun 18;105(24):2867-71 [PMID: 12070115]
  19. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8880-5 [PMID: 12072561]
  20. J Heart Lung Transplant. 2002 Jul;21(7):771-82 [PMID: 12100903]
  21. Nucl Med Commun. 2002 Sep;23(9):871-7 [PMID: 12195092]
  22. Clin Cancer Res. 2002 Nov;8(11):3360-8 [PMID: 12429622]
  23. Oncogene. 2002 Dec 9;21(56):8547-59 [PMID: 12476301]
  24. Toxicol Appl Pharmacol. 2002 Dec 15;185(3):218-27 [PMID: 12498738]
  25. N Engl J Med. 2003 Mar 13;348(11):994-1004 [PMID: 12637609]
  26. Leukemia. 2003 Apr;17(4):804-5 [PMID: 12682642]
  27. Cancer. 2003 Jun 1;97(11):2869-79 [PMID: 12767102]
  28. Br J Cancer. 2003 May 19;88(10):1507-9 [PMID: 12771913]
  29. J Pharmacol Exp Ther. 1992 Oct;263(1):92-8 [PMID: 1357162]
  30. Cell. 2003 Sep 19;114(6):763-76 [PMID: 14505575]
  31. J Cancer Res Clin Oncol. 2004 Jan;130(1):1-7 [PMID: 14564513]
  32. Nat Med. 2003 Dec;9(12):1477-83 [PMID: 14595408]
  33. J Biol Chem. 2004 Feb 27;279(9):8290-9 [PMID: 14676206]
  34. Cardiovasc Toxicol. 2003;3(4):319-29 [PMID: 14734829]
  35. Cancer Control. 2004 Jan-Feb;11(1):46-9 [PMID: 14749623]
  36. Blood. 2004 Jul 1;104(1):149-58 [PMID: 15016650]
  37. FASEB J. 2004 Apr;18(6):664-75 [PMID: 15054088]
  38. Circulation. 2004 Jun 8;109(22):2773-9 [PMID: 15148268]
  39. Circulation. 2004 Jun 8;109(22):2749-54 [PMID: 15148277]
  40. Pharmacol Rev. 2004 Jun;56(2):185-229 [PMID: 15169927]
  41. N Engl J Med. 2004 Jun 3;350(23):2335-42 [PMID: 15175435]
  42. Jpn J Clin Oncol. 2004 May;34(5):262-8 [PMID: 15231861]
  43. J Am Coll Cardiol. 2004 Sep 1;44(5):1030-5 [PMID: 15337215]
  44. J Mol Cell Cardiol. 2004 Oct;37(4):837-46 [PMID: 15380674]
  45. Circ Res. 2004 Oct 29;95(9):911-21 [PMID: 15472116]
  46. Med Hypotheses. 2005;64(3):476-8 [PMID: 15617852]
  47. Eur Heart J. 2005 Mar;26(6):607-16 [PMID: 15618026]
  48. Eur J Heart Fail. 2005 Jan;7(1):87-93 [PMID: 15642537]
  49. J Clin Oncol. 2005 Feb 1;23(4):792-9 [PMID: 15681523]
  50. Basic Res Cardiol. 2005 May;100(3):240-9 [PMID: 15685397]
  51. Circulation. 2005 Apr 5;111(13):1601-10 [PMID: 15811867]
  52. J Clin Oncol. 2005 May 1;23(13):2900-2 [PMID: 15860848]
  53. Clin Chem. 2005 Aug;51(8):1405-10 [PMID: 15932966]
  54. Eur J Echocardiogr. 2006 Mar;7(2):141-6 [PMID: 15941672]
  55. Eur J Cancer. 2005 Jul;41(11):1542-6 [PMID: 15978800]
  56. J Clin Invest. 2005 Oct;115(10):2811-21 [PMID: 16200212]
  57. Cancer. 2005 Dec 1;104(11):2492-8 [PMID: 16247790]
  58. J Clin Oncol. 2005 Nov 1;23(31):7820-6 [PMID: 16258084]
  59. J Pathol. 2005 Dec;207(4):436-44 [PMID: 16278810]
  60. Int J Cardiol. 2006 Jun 28;110(3):378-85 [PMID: 16324756]
  61. J Clin Oncol. 2006 Jan 1;24(1):16-24 [PMID: 16330672]
  62. Br J Haematol. 2005 Dec;131(5):561-78 [PMID: 16351632]
  63. Cancer Chemother Pharmacol. 2006 Oct;58(4):487-93 [PMID: 16418875]
  64. Curr Cardiol Rep. 2006 Mar;8(2):131-8 [PMID: 16524540]
  65. Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):1-5 [PMID: 16529545]
  66. J Biol Chem. 2006 May 26;281(21):14554-62 [PMID: 16543234]
  67. Hypertension. 2006 May;47(5):827-9 [PMID: 16567590]
  68. Hypertension. 2006 May;47(5):887-93 [PMID: 16567591]
  69. J Clin Oncol. 2006 May 20;24(15):2276-82 [PMID: 16710024]
  70. N Engl J Med. 2006 Jun 15;354(24):2531-41 [PMID: 16775234]
  71. N Engl J Med. 2006 Jun 15;354(24):2542-51 [PMID: 16775235]
  72. Nat Med. 2006 Aug;12(8):908-16 [PMID: 16862153]
  73. Hum Exp Toxicol. 2006 Jun;25(6):305-9 [PMID: 16866187]
  74. Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1329-37 [PMID: 16910780]
  75. J Mol Cell Cardiol. 2006 Oct;41(4):567-79 [PMID: 16949602]
  76. J Mol Cell Cardiol. 2006 Nov;41(5):845-54 [PMID: 17005195]
  77. J Am Coll Cardiol. 2006 Oct 3;48(7):1438-47 [PMID: 17010808]
  78. N Engl J Med. 2006 Oct 12;355(15):1572-82 [PMID: 17035650]
  79. Circulation. 2006 Dec 5;114(23):2474-81 [PMID: 17101852]
  80. FASEB J. 2007 Feb;21(2):618-28 [PMID: 17135364]
  81. J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62 [PMID: 17161256]
  82. N Engl J Med. 2006 Dec 14;355(24):2542-50 [PMID: 17167137]
  83. Nat Med. 2007 Jan;13(1):13-4; author reply 15-6 [PMID: 17206117]
  84. Nat Med. 2007 Jan;13(1):13; author reply 15-6 [PMID: 17206118]
  85. Nat Med. 2007 Jan;13(1):14; author reply 15-6 [PMID: 17206119]
  86. Nat Med. 2007 Jan;13(1):15; author reply 15-6 [PMID: 17206121]
  87. N Engl J Med. 2007 Jan 11;356(2):115-24 [PMID: 17215529]
  88. Circulation. 2007 Feb 20;115(7):896-908 [PMID: 17283259]
  89. Apoptosis. 2007 May;12(5):877-85 [PMID: 17294083]
  90. Cancer Res. 2007 Feb 15;67(4):1436-41 [PMID: 17308081]
  91. J Nucl Med. 1992 Feb;33(2):208-14 [PMID: 1732442]
  92. Nature. 2007 Mar 22;446(7134):444-8 [PMID: 17334357]
  93. Leuk Res. 2007 Dec;31(12):1770-2 [PMID: 17382388]
  94. Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [PMID: 17396134]
  95. Nat Rev Cancer. 2007 May;7(5):332-44 [PMID: 17457301]
  96. J Clin Oncol. 2007 Sep 1;25(25):3991-4008 [PMID: 17577017]
  97. Pediatr Blood Cancer. 2007 Nov;49(6):835-40 [PMID: 17610264]
  98. J Cancer Res Clin Oncol. 2008 Jan;134(1):75-82 [PMID: 17636329]
  99. J Clin Oncol. 2007 Sep 1;25(25):3859-65 [PMID: 17646669]
  100. Cell. 2007 Aug 24;130(4):691-703 [PMID: 17719546]
  101. Eur J Cancer. 2007 Sep;43(14):2046-51 [PMID: 17719768]
  102. J Clin Oncol. 2007 Sep 1;25(25):3908-14 [PMID: 17761974]
  103. Circ Res. 2007 Oct 26;101(9):865-74 [PMID: 17823377]
  104. Cancer Res. 2007 Sep 15;67(18):8839-46 [PMID: 17875725]
  105. N Engl J Med. 2007 Oct 25;357(17):1695-704 [PMID: 17960012]
  106. J Clin Invest. 2007 Nov;117(11):3176-9 [PMID: 17975662]
  107. Lancet. 2007 Dec 15;370(9604):2011-9 [PMID: 18083403]
  108. Development. 2008 Jan;135(2):193-205 [PMID: 18156162]
  109. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):282-7 [PMID: 18162550]
  110. Eur J Cancer. 2008 Feb;44(3):334-40 [PMID: 18194856]
  111. J Clin Oncol. 2008 Mar 10;26(8):1201-3 [PMID: 18227525]
  112. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Dec;151(2):247-9 [PMID: 18345258]
  113. J Clin Oncol. 2008 Apr 10;26(11):1810-6 [PMID: 18347007]
  114. Chem Res Toxicol. 2008 May;21(5):978-89 [PMID: 18376852]
  115. Cancer. 2008 Jun;112(11):2500-8 [PMID: 18386829]
  116. Ann Oncol. 2008 Sep;19(9):1613-8 [PMID: 18436521]
  117. Exp Oncol. 2008 Jun;30(2):157-9 [PMID: 18566582]
  118. Nat Med. 2008 Jul;14(7):731-7 [PMID: 18568034]
  119. J Clin Oncol. 2008 Jul 1;26(19):3122-4 [PMID: 18591552]
  120. Ann Oncol. 2008 Sep;19(9):1656-7 [PMID: 18622008]
  121. Pharmacol Rep. 2008 May-Jun;60(3):382-90 [PMID: 18622063]
  122. Toxicol Sci. 2008 Nov;106(1):153-61 [PMID: 18664550]
  123. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60 [PMID: 18787115]
  124. Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2149-55 [PMID: 18820026]
  125. J Clin Oncol. 2008 Nov 10;26(32):5204-12 [PMID: 18838713]
  126. Ann Oncol. 2009 Feb;20(2):227-30 [PMID: 18842611]
  127. J Thromb Haemost. 2009 Jan;7(1):21-33 [PMID: 18983480]
  128. J Mol Cell Cardiol. 2009 Jan;46(1):33-8 [PMID: 19010331]
  129. Toxicology. 2009 Jan 8;255(1-2):72-9 [PMID: 19010377]
  130. Circ Res. 2009 Feb 13;104(3):403-11 [PMID: 19096023]
  131. Cancer Res. 2009 Jan 15;69(2):695-9 [PMID: 19147586]
  132. Anticancer Drugs. 2009 Apr;20(4):217-29 [PMID: 19247178]
  133. Ann Pharmacother. 2009 Mar;43(3):490-501 [PMID: 19261963]
  134. J Am Soc Echocardiogr. 2009 Apr;22(4):418-24 [PMID: 19269133]
  135. Pharmacol Rep. 2009 Jan-Feb;61(1):154-71 [PMID: 19307704]
  136. NMR Biomed. 2009 Jul;22(6):585-92 [PMID: 19308947]
  137. Target Oncol. 2009 Apr;4(2):99-105 [PMID: 19381453]
  138. Circ Res. 2009 Jun 5;104(11):1302-12 [PMID: 19443835]
  139. Ann Oncol. 2009 Sep;20(9):1535-42 [PMID: 19474115]
  140. J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47 [PMID: 19520246]
  141. Am Heart J. 2009 Aug;158(2):294-301 [PMID: 19619708]
  142. Clin Cancer Res. 2009 Aug 1;15(15):4963-7 [PMID: 19622583]
  143. Hypertension. 2009 Sep;54(3):652-8 [PMID: 19652084]
  144. Circulation. 1990 Aug;82(2):473-83 [PMID: 1973638]
  145. J Natl Cancer Inst. 2010 Jan 6;102(1):14-25 [PMID: 20007921]
  146. Circulation. 2010 Jan 19;121(2):276-92 [PMID: 20038740]
  147. Circ Res. 2010 Jan 8;106(1):21-34 [PMID: 20056943]
  148. Circ Res. 2010 Jan 8;106(1):35-46 [PMID: 20056944]
  149. J Clin Invest. 2010 Feb;120(2):472-84 [PMID: 20071776]
  150. Circulation. 2010 Feb 9;121(5):675-83 [PMID: 20100968]
  151. Am J Cardiol. 2010 Feb 15;105(4):522-6 [PMID: 20152248]
  152. Acta Oncol. 2010 Apr;49(3):287-97 [PMID: 20156114]
  153. J Pharmacol Exp Ther. 2010 Jul;334(1):2-8 [PMID: 20335321]
  154. Circulation. 2010 Apr 13;121(14):1606-13 [PMID: 20351235]
  155. J Clin Oncol. 2010 May 1;28(13):2280-5 [PMID: 20351323]
  156. J Natl Cancer Inst. 2010 May 5;102(9):596-604 [PMID: 20351338]
  157. Clin Transl Sci. 2009 Feb;2(1):15-25 [PMID: 20376335]
  158. Int Immunol. 2010 Jun;22(6):443-52 [PMID: 20410257]
  159. Heart. 2010 May;96(9):701-7 [PMID: 20424152]
  160. Ann Oncol. 2010 Nov;21(11):2220-6 [PMID: 20427348]
  161. J Am Coll Cardiol. 2010 May 4;55(18):1907-14 [PMID: 20430261]
  162. J Clin Endocrinol Metab. 2010 Aug;95(8):3763-7 [PMID: 20466781]
  163. Cardiovasc Res. 2010 Sep 1;87(4):656-64 [PMID: 20495188]
  164. Am J Pathol. 2010 Jun;176(6):2658-68 [PMID: 20519734]
  165. N Engl J Med. 2010 Aug 19;363(8):711-23 [PMID: 20525992]
  166. J Clin Oncol. 2010 Jul 20;28(21):3429-36 [PMID: 20530277]
  167. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1023-30 [PMID: 20543097]
  168. Antioxid Redox Signal. 2011 Mar 1;14(5):833-50 [PMID: 20649460]
  169. J Clin Oncol. 2010 Sep 1;28(25):3910-6 [PMID: 20679614]
  170. J Clin Oncol. 2010 Sep 1;28(25):3901-4 [PMID: 20679626]
  171. Exp Oncol. 2010 Jul;32(2):97-9 [PMID: 20693970]
  172. J Mol Cell Cardiol. 2011 Feb;50(2):280-9 [PMID: 20727900]
  173. Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):114-20 [PMID: 20728698]
  174. Eur J Heart Fail. 2011 Jan;13(1):83-92 [PMID: 20810473]
  175. Am Heart J. 2010 Sep;160(3):487.e1-7 [PMID: 20826257]
  176. Toxicol Appl Pharmacol. 2010 Dec 1;249(2):132-9 [PMID: 20832415]
  177. Lancet Oncol. 2010 Oct;11(10):950-61 [PMID: 20850381]
  178. PLoS One. 2010 Sep 15;5(9):e12733 [PMID: 20856801]
  179. Int J Cardiol. 2012 Feb 9;154(3):282-6 [PMID: 20974500]
  180. Leuk Res. 2011 Jan;35(1):49-51 [PMID: 21030079]
  181. Pharmacogenet Genomics. 2011 Jul;21(7):440-6 [PMID: 21048526]
  182. Eur J Heart Fail. 2011 Jan;13(1):1-10 [PMID: 21169385]
  183. Nat Rev Drug Discov. 2011 Feb;10(2):111-26 [PMID: 21283106]
  184. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [PMID: 21296855]
  185. Leuk Res. 2011 Jun;35(6):715-20 [PMID: 21333352]
  186. Int J Cardiol. 2011 May 19;149(1):114-5 [PMID: 21342707]
  187. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  188. J Clin Oncol. 2011 May 1;29(13):1757-64 [PMID: 21422411]
  189. J Clin Oncol. 2011 May 20;29(15):2004-10 [PMID: 21464401]
  190. Curr Hypertens Rep. 2011 Aug;13(4):289-93 [PMID: 21479992]
  191. Am J Hematol. 2011 Jul;86(7):533-9 [PMID: 21538470]
  192. Cancer Chemother Pharmacol. 2012 Jan;69(1):57-64 [PMID: 21603868]
  193. J Am Coll Cardiol. 2011 May 31;57(22):2263-70 [PMID: 21616287]
  194. Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36 [PMID: 21635149]
  195. J Clin Oncol. 2011 Aug 20;29(24):e691-3 [PMID: 21709191]
  196. Breast J. 2011 Sep-Oct;17(5):564-5; author reply 566-7 [PMID: 21726348]
  197. BMC Cancer. 2011 Jul 27;11:318 [PMID: 21794114]
  198. Cardiovasc Diabetol. 2011 Jul 29;10:69 [PMID: 21798071]
  199. Circulation. 2011 Aug 2;124(5):642-50 [PMID: 21810673]
  200. J Clin Oncol. 2011 Sep 1;29(25):3450-6 [PMID: 21810682]
  201. J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8 [PMID: 21813414]
  202. Cell Stem Cell. 2011 Aug 5;9(2):131-43 [PMID: 21816364]
  203. Cell Death Dis. 2011 Aug 11;2:e190 [PMID: 21833028]
  204. Blood. 2011 Oct 27;118(17):4567-76 [PMID: 21865346]
  205. Haematologica. 2011 Oct;96(10):1395-7 [PMID: 21972208]
  206. Circulation. 2011 Oct 11;124(15):1687-91 [PMID: 21986775]
  207. Chemotherapy. 2011;57(5):381-7 [PMID: 21997165]
  208. Lancet. 2011 Dec 3;378(9807):1931-9 [PMID: 22056247]
  209. Br J Cancer. 2011 Nov 22;105(11):1663-8 [PMID: 22068815]
  210. Cytotherapy. 2012 Apr;14(4):412-22 [PMID: 22242830]
  211. Am Heart J. 2012 Feb;163(2):156-63 [PMID: 22305831]
  212. Lancet. 2012 Mar 10;379(9819):895-904 [PMID: 22336189]
  213. Clin Ther. 2012 Mar;34(3):511-20 [PMID: 22341567]
  214. Diabetes. 2012 Apr;61(4):944-53 [PMID: 22344560]
  215. PLoS One. 2012;7(2):e30353 [PMID: 22363427]
  216. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [PMID: 22437870]
  217. Circulation. 2012 May 1;125(17):2128-37 [PMID: 22451584]
  218. Nitric Oxide. 2012 May 15;26(4):274-84 [PMID: 22484629]
  219. J Immunol. 2012 May 15;188(10):4876-84 [PMID: 22491251]
  220. BJU Int. 2012 Nov;110(10):1455-62 [PMID: 22508007]
  221. J Clin Oncol. 2012 Jul 20;30(21):2691-7 [PMID: 22614989]
  222. N Engl J Med. 2012 Jun 28;366(26):2443-54 [PMID: 22658127]
  223. Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10921-6 [PMID: 22711842]
  224. Int J Cardiol. 2013 Sep 1;167(5):2306-10 [PMID: 22727976]
  225. Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603 [PMID: 22744937]
  226. Nutrition. 2013 Jan;29(1):15-21 [PMID: 22784609]
  227. Eur Heart J. 2013 Apr;34(15):1102-11 [PMID: 22789916]
  228. Antioxid Redox Signal. 2013 Mar 10;18(8):899-929 [PMID: 22794198]
  229. J Clin Oncol. 2012 Oct 1;30(28):3486-92 [PMID: 22949154]
  230. Exp Ther Med. 2011 Sep;2(5):1003-1009 [PMID: 22977612]
  231. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66 [PMID: 22997448]
  232. Cardiol J. 2012;19(5):453-8 [PMID: 23042307]
  233. Circulation. 2012 Dec 4;126(23):2728-38 [PMID: 23099479]
  234. Nat Med. 2012 Nov;18(11):1639-42 [PMID: 23104132]
  235. Circ Res. 2012 Oct 26;111(10):1376-85 [PMID: 23104879]
  236. J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90 [PMID: 23141499]
  237. Pediatrics. 2012 Dec;130(6):1003-11 [PMID: 23166343]
  238. Int J Hematol. 2013 Jan;97(1):135-8 [PMID: 23179903]
  239. N Engl J Med. 2012 Nov 29;367(22):2075-88 [PMID: 23190221]
  240. Cardiovasc Res. 2013 Mar 1;97(3):432-42 [PMID: 23208587]
  241. Eur J Heart Fail. 2013 May;15(5):482-9 [PMID: 23325019]
  242. PLoS One. 2013;8(1):e53745 [PMID: 23341990]
  243. N Engl J Med. 2013 Jan 31;368(5):455-64 [PMID: 23363499]
  244. Circ Heart Fail. 2013 May;6(3):420-6 [PMID: 23425978]
  245. PLoS One. 2013;8(2):e57554 [PMID: 23437398]
  246. Leukemia. 2013 Jun;27(6):1316-21 [PMID: 23459449]
  247. Leukemia. 2013 Jun;27(6):1310-5 [PMID: 23459450]
  248. J Cancer Sci Ther. 2013;5(2):52-57 [PMID: 23459697]
  249. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4275-9 [PMID: 2349236]
  250. N Engl J Med. 2013 Mar 21;368(12):1154-6 [PMID: 23514294]
  251. Semin Oncol. 2013 Apr;40(2):218-28 [PMID: 23540747]
  252. Cancer Treat Rev. 2013 Dec;39(8):974-84 [PMID: 23582737]
  253. J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62 [PMID: 23583763]
  254. JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85 [PMID: 23643285]
  255. Circ Heart Fail. 2013 May;6(3):358-61 [PMID: 23694770]
  256. Br J Clin Pharmacol. 2013 Aug;76(2):233-47 [PMID: 23701301]
  257. Eur J Cancer. 2013 Sep;49(13):2900-9 [PMID: 23706982]
  258. Haematologica. 2013 Oct;98(10):e124-6 [PMID: 23716549]
  259. Sci Transl Med. 2013 May 29;5(187):187ra69 [PMID: 23720580]
  260. J Cardiol. 2013 Aug;62(2):110-6 [PMID: 23731918]
  261. Springerplus. 2013 Apr 30;2(1):198 [PMID: 23741643]
  262. Fundam Clin Pharmacol. 2014 Jun;28(3):349-52 [PMID: 23781941]
  263. Int J Cancer. 2014 May 15;134(10):2269-77 [PMID: 23784914]
  264. Basic Res Cardiol. 2013 Jul;108(4):366 [PMID: 23812247]
  265. J Pharmacol Exp Ther. 2013 Sep;346(3):343-9 [PMID: 23818683]
  266. Oncoimmunology. 2013 Jun 1;2(6):e24786 [PMID: 23894723]
  267. J Clin Invest. 2013 Aug;123(8):3190-200 [PMID: 23908119]
  268. Nat Commun. 2013;4:2308 [PMID: 23917356]
  269. Oncologist. 2013;18(8):900-8 [PMID: 23918069]
  270. Cancer Chemother Pharmacol. 2013 Dec;72(6):1157-68 [PMID: 23959462]
  271. N Engl J Med. 2013 Aug 22;369(8):722-31 [PMID: 23964934]
  272. PLoS One. 2013 Aug 20;8(8):e71980 [PMID: 23977191]
  273. Circ Res. 2013 Aug 30;113(6):754-64 [PMID: 23989717]
  274. Eur Respir Rev. 2013 Sep 1;22(129):244-50 [PMID: 23997051]
  275. Nat Med. 2013 Sep;19(9):1100-1 [PMID: 24013749]
  276. Oncoimmunology. 2013 Aug 1;2(8):e25961 [PMID: 24083084]
  277. N Engl J Med. 2013 Nov 7;369(19):1783-96 [PMID: 24180494]
  278. Lancet Oncol. 2013 Dec;14(13):1287-94 [PMID: 24206640]
  279. Crit Rev Oncol Hematol. 2014 Feb;89(2):242-7 [PMID: 24210599]
  280. Chem Immunol Allergy. 2014;99:XI-XII [PMID: 24217613]
  281. Curr Heart Fail Rep. 2014 Mar;11(1):40-9 [PMID: 24234399]
  282. Breast Cancer Res Treat. 2013 Dec;142(3):645-53 [PMID: 24241607]
  283. Circ Cardiovasc Imaging. 2013 Nov;6(6):1080-91 [PMID: 24254478]
  284. Cancers (Basel). 2010 Sep 17;2(3):1717-30 [PMID: 24281184]
  285. J Am Coll Cardiol. 2014 Mar 4;63(8):809-16 [PMID: 24291281]
  286. Am J Clin Oncol. 2016 Feb;39(1):76-84 [PMID: 24351780]
  287. PLoS One. 2013 Dec 19;8(12):e85231 [PMID: 24367707]
  288. J Clin Invest. 2014 Feb;124(2):617-30 [PMID: 24382354]
  289. Lancet Oncol. 2014 Feb;15(2):143-55 [PMID: 24411639]
  290. Nat Rev Clin Oncol. 2014 Feb;11(2):91-9 [PMID: 24445516]
  291. Eur J Heart Fail. 2014 Apr;16(4):358-66 [PMID: 24464789]
  292. PLoS One. 2014 Jan 29;9(1):e87671 [PMID: 24489948]
  293. Ann Oncol. 2014 May;25(5):1059-64 [PMID: 24558023]
  294. Hypertension. 2014 Jun;63(6):1228-34 [PMID: 24591339]
  295. Cell Transplant. 2015;24(6):1043-52 [PMID: 24593859]
  296. Front Pharmacol. 2014 Feb 26;5:25 [PMID: 24616701]
  297. Expert Rev Cardiovasc Ther. 2014 Apr;12(4):487-97 [PMID: 24650314]
  298. Haematologica. 2014 Jul;99(7):1197-203 [PMID: 24658819]
  299. Exp Biol Med (Maywood). 2014 Jun;239(6):647-62 [PMID: 24668550]
  300. Toxicol Lett. 2014 Jun 16;227(3):151-6 [PMID: 24704391]
  301. J Cell Mol Med. 2014 Jun;18(6):947-61 [PMID: 24712303]
  302. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6323-8 [PMID: 24733928]
  303. J Am Heart Assoc. 2014 Apr 22;3(2):e000665 [PMID: 24755151]
  304. Nature. 2014 May 15;509(7500):337-41 [PMID: 24805242]
  305. Leuk Res. 2014 Jul;38(7):781-7 [PMID: 24832371]
  306. Br J Clin Pharmacol. 2014 Nov;78(5):950-60 [PMID: 24844787]
  307. J Med Case Rep. 2014 Jun 23;8:220 [PMID: 24957905]
  308. PLoS One. 2014 Jul 02;9(7):e101024 [PMID: 24988225]
  309. Curr Oncol Rep. 2014;16(8):396 [PMID: 24992733]
  310. PLoS One. 2014 Jul 18;9(7):e102758 [PMID: 25036594]
  311. Curr Cancer Drug Targets. 2014;14(6):517-36 [PMID: 25092212]
  312. J Am Coll Cardiol. 2014 Sep 2;64(9):938-45 [PMID: 25169180]
  313. BMC Pharmacol Toxicol. 2014 Sep 04;15:47 [PMID: 25186061]
  314. Science. 2014 Sep 26;345(6204):1623-1627 [PMID: 25213377]
  315. Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93 [PMID: 25239940]
  316. J Clin Oncol. 2015 Feb 10;33(5):394-402 [PMID: 25287823]
  317. Onco Targets Ther. 2014 Sep 29;7:1783-91 [PMID: 25302025]
  318. Br J Pharmacol. 2015 Apr;172(8):1974-95 [PMID: 25303224]
  319. J Am Heart Assoc. 2014 Oct 23;3(5):e000773 [PMID: 25341890]
  320. Circ Heart Fail. 2015 Jan;8(1):98-108 [PMID: 25420486]
  321. J Card Fail. 2015 Feb;21(2):138-44 [PMID: 25433360]
  322. Pharmacol Res. 2015 Jan;91:47-56 [PMID: 25462173]
  323. Lancet. 2015 Feb 28;385(9970):812-24 [PMID: 25467564]
  324. J Cardiovasc Med (Hagerstown). 2015 Aug;16(8):527-37 [PMID: 25469729]
  325. Nat Med. 2014 Dec;20(12):1386-93 [PMID: 25473919]
  326. N Engl J Med. 2015 Jan 8;372(2):142-52 [PMID: 25482145]
  327. Lancet. 2015 Apr 11;385(9976):1447-59 [PMID: 25484026]
  328. Expert Opin Drug Saf. 2015 Feb;14(2):253-67 [PMID: 25494575]
  329. Nat Rev Immunol. 2015 Jan;15(1):45-56 [PMID: 25534622]
  330. Am J Hematol. 2015 Apr;90(4):E66-72 [PMID: 25580915]
  331. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1880-5 [PMID: 25583515]
  332. Blood Cancer J. 2015 Jan 16;5:e272 [PMID: 25594159]
  333. Can J Cardiol. 2015 Mar;31(3):302-7 [PMID: 25662284]
  334. Nat Rev Cardiol. 2015 Apr;12(4):220-9 [PMID: 25666406]
  335. Transl Med UniSa. 2014 Dec 19;11:39-43 [PMID: 25674548]
  336. Ann Intern Med. 1989 Aug 15;111(4):273-9 [PMID: 2569287]
  337. J Immunother Cancer. 2015 Feb 17;3:4 [PMID: 25705383]
  338. Curr Drug Targets. 2015;16(8):895-903 [PMID: 25738298]
  339. Br J Cancer. 2015 Mar 17;112(6):1011-6 [PMID: 25742483]
  340. Eur Heart J Cardiovasc Imaging. 2015 May;16(5):466-70 [PMID: 25744342]
  341. Br J Haematol. 2015 Aug;170(3):291-304 [PMID: 25824455]
  342. Science. 2015 Apr 3;348(6230):56-61 [PMID: 25838373]
  343. Nat Cell Biol. 2015 May;17(5):627-38 [PMID: 25848746]
  344. Cancer Cell. 2015 Apr 13;27(4):450-61 [PMID: 25858804]
  345. Cell. 2015 Apr 9;161(2):205-14 [PMID: 25860605]
  346. Br J Pharmacol. 2015 Mar;172(6):1395-6 [PMID: 25891246]
  347. J Immunother Cancer. 2015 Apr 21;3:11 [PMID: 25901283]
  348. Eur Heart J. 2015 Aug 14;36(31):2050-2060 [PMID: 25911648]
  349. Case Rep Oncol Med. 2015;2015:794842 [PMID: 25918658]
  350. Circulation. 2015 Jun 2;131(22):1981-8 [PMID: 25948538]
  351. Int J Cardiol. 2015 Jul 15;191:203-10 [PMID: 25974196]
  352. Eur J Immunol. 2015 Jul;45(7):1892-905 [PMID: 26018646]
  353. Am J Hypertens. 2016 Feb;29(2):158-62 [PMID: 26031304]
  354. Heart Fail Rev. 2015 Sep;20(5):621-31 [PMID: 26168714]
  355. Stem Cells. 2015 Oct;33(10):3100-13 [PMID: 26184084]
  356. Acta Biochim Pol. 2015;62(3):329-37 [PMID: 26200199]
  357. Future Cardiol. 2015 Jul;11(4):363-6 [PMID: 26239550]
  358. Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1271-80 [PMID: 26254336]
  359. Am J Hematol. 2015 Nov;90(11):1060-4 [PMID: 26284693]
  360. J Oncol. 2015;2015:263950 [PMID: 26300915]
  361. Eur J Haematol. 2016 Jul;97(1):25-32 [PMID: 26331915]
  362. J Oncol. 2015;2015:917606 [PMID: 26339243]
  363. J Clin Oncol. 2015 Dec 10;33(35):4210-8 [PMID: 26371140]
  364. Oncotarget. 2015 Oct 20;6(32):33944-51 [PMID: 26376678]
  365. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67 [PMID: 26386112]
  366. Nat Commun. 2015 Oct 30;6:8701 [PMID: 26515110]
  367. Br J Haematol. 2016 Jan;172(1):97-110 [PMID: 26537529]
  368. Thromb Haemost. 2015 Nov 25;114(6):1100-3 [PMID: 26559693]
  369. Biomed Res Int. 2015;2015:138148 [PMID: 26583088]
  370. Ann Transl Med. 2015 Oct;3(18):267 [PMID: 26605313]
  371. Eur J Cancer. 2016 Jan;52:50-66 [PMID: 26645943]
  372. Lancet Haematol. 2015 May;2(5):e186-93 [PMID: 26688093]
  373. Cardiovasc Res. 2016 Mar 1;109(3):358-73 [PMID: 26692570]
  374. J Mol Cell Cardiol. 2016 Feb;91:92-103 [PMID: 26724189]
  375. J Am Heart Assoc. 2016 Jan 08;5(1):null [PMID: 26746999]
  376. Circ Heart Fail. 2016 Jan;9(1):e002661 [PMID: 26747861]
  377. Eur J Cancer. 2016 Feb;54:139-148 [PMID: 26765102]
  378. Blood Cancer J. 2016 Jan 15;6:e384 [PMID: 26771810]
  379. Mol Nutr Food Res. 2016 Jun;60(6):1406-15 [PMID: 26829056]
  380. Circ Res. 2016 Jan 8;118(1):17-9 [PMID: 26837741]
  381. Leukemia. 2016 May;30(5):1044-54 [PMID: 26837842]
  382. Circ Heart Fail. 2016 Feb;9(2):e002843 [PMID: 26839395]
  383. JAMA Oncol. 2016 May 1;2(5):625-632 [PMID: 26847662]
  384. Eur Heart J. 2016 Jun 1;37(21):1671-80 [PMID: 26903532]
  385. Curr Treat Options Cardiovasc Med. 2016 May;18(5):33 [PMID: 26932588]
  386. N Engl J Med. 2016 Mar 3;374(9):896-8 [PMID: 26962927]
  387. Am J Hematol. 2016 Jun;91(6):606-16 [PMID: 26971533]
  388. Eur Heart J. 2016 Jun 14;37(23):1789-98 [PMID: 27055812]
  389. Lancet Oncol. 2016 May;17(5):612-21 [PMID: 27083332]
  390. J Card Fail. 2016 Jun;22(6):449-58 [PMID: 27103426]
  391. Toxicology. 2016 Apr 15;353-354:34-47 [PMID: 27155237]
  392. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S27-34 [PMID: 27183522]
  393. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S3-S11 [PMID: 27183523]
  394. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S35-44 [PMID: 27183524]
  395. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S45-54 [PMID: 27183525]
  396. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S64-75 [PMID: 27183527]
  397. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S76-83 [PMID: 27183528]
  398. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S84-92 [PMID: 27183529]
  399. Am J Hematol. 2016 Sep;91(9):869-74 [PMID: 27192969]
  400. Eur J Heart Fail. 2016 Aug;18(8):891-975 [PMID: 27207191]
  401. J Clin Oncol. 2016 Jul 10;34(20):2333-40 [PMID: 27217448]
  402. Heart Fail Rev. 2016 Sep;21(5):621-34 [PMID: 27230651]
  403. Ann Intern Med. 2016 Aug 2;165(3):161-6 [PMID: 27295519]
  404. Immunity. 2016 Jun 21;44(6):1255-69 [PMID: 27332730]
  405. Antioxid Redox Signal. 2016 Aug 20;25(6):300-25 [PMID: 27353526]
  406. J Hematol Oncol. 2016 Jun 30;9(1):52 [PMID: 27363832]
  407. BMC Cancer. 2016 Jul 04;16:386 [PMID: 27377645]
  408. Cardiovasc Toxicol. 2017 Jul;17(3):237-250 [PMID: 27388042]
  409. Int J Cardiol. 2016 Oct 15;221:396-403 [PMID: 27404713]
  410. Mitochondrion. 2016 Sep;30:95-104 [PMID: 27423789]
  411. J Clin Invest. 2016 Sep 1;126(9):3207-18 [PMID: 27482885]
  412. Thromb Res. 2016 Sep;145:54-64 [PMID: 27494773]
  413. Oncotarget. 2016 Nov 1;7(44):72311-72321 [PMID: 27527867]
  414. J Immunother Cancer. 2016 Aug 16;4:50 [PMID: 27532025]
  415. Eur Heart J. 2016 Sep 21;37(36):2768-2801 [PMID: 27567406]
  416. Ann Hematol. 2017 Apr;96(4):549-558 [PMID: 27686083]
  417. Cardiovasc Toxicol. 2017 Jul;17(3):297-306 [PMID: 27696211]
  418. N Engl J Med. 2016 Oct 13;375(15):1457-1467 [PMID: 27732808]
  419. Science. 1987 Jan 9;235(4785):177-82 [PMID: 3798106]
  420. Cardiovasc Res. 1985 Jun;19(6):378-82 [PMID: 4016815]
  421. Cancer. 1967 Mar;20(3):333-53 [PMID: 4290058]
  422. N Engl J Med. 1971 Nov 18;285(21):1182-6 [PMID: 4938153]
  423. J Exp Med. 1995 Aug 1;182(2):459-65 [PMID: 7543139]
  424. J Natl Cancer Inst Monogr. 1993;(15):117-30 [PMID: 7912518]
  425. Int J Cardiol. 1994 Mar 15;44(1):9-18 [PMID: 8021056]
  426. Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15 [PMID: 8102012]
  427. Eur J Nucl Med. 1996 Apr;23(4):453-8 [PMID: 8612668]
  428. J Clin Oncol. 1997 Apr;15(4):1318-32 [PMID: 9193323]
  429. Pharmacotherapy. 1997 Jul-Aug;17(4):729-36 [PMID: 9250550]
  430. Circulation. 1997 Oct 21;96(8):2641-8 [PMID: 9355905]
  431. J Nucl Cardiol. 1997 Nov-Dec;4(6):502-8 [PMID: 9456190]
  432. Am Heart J. 1998 Aug;136(2):362-3 [PMID: 9704703]

MeSH Term

Antineoplastic Agents
Cardiotoxicity
Humans
Mitochondria
Oxidation-Reduction

Chemicals

Antineoplastic Agents
Journal Article Research Support, Non-U.S. Gov't Review

Word Cloud

Created with Highcharts 10.0.0CTXpatientstreatmentsmechanismsredoxriskcancerAntineoplastictherapiescancardiovascularkeydataantineoplasticanti-cancertreatmentTypeassociatedcausedclinicalmayinhibitorssignificantlyimprovedprognosisoncologyHoweverbringhigherincidenceside-effectsincludingworryingtoxicitySubstantialevidenceindicatesmultipleplayingroleRecentsingledmitochondriatargetsdrug-inducedunderstandingunderlyingthereforecrucialeffectivecardioprotectionwithoutcompromisingefficacyoccurwithindaysmanyyearsirreversiblecardiaccellinjurytypicallyanthracyclinestraditionalchemotherapeuticsIIgenerallynovelbiologicstargeteddrugsreversiblemyocardialdysfunctionThereforeundergoingcloselymonitoredidentifiedbeginningreduceCTX-relatedmorbidityGeneticprofilingfactorsintegratedapproachusingmolecularimagingallowrecognitionhighdevelopingchemotherapy-relatedsuggestmethodologieslimitdamagewiderrangeinvolvementbiologyanticanceractivefieldresearchinvestigationswillnecessaryuncoverhallmarksperspectivedevelopefficaciousalsosparesystemMolecularMechanismsClinicalManagementDrug-InducedCardiovascularToxicity:TranslationalOverviewErbB2immunotherapychemotherapyoxidative/nitrosativestresstyrosinekinasevascularendothelialgrowthfactor

Similar Articles

Cited By